Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life

Background: Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials. Methods: These analyses included data for Investigator's Global Assessment responder (clear [0] or almost clear [1] with >= 2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib mono-therapy trials (phase 2b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/ JADE MONO-2). Outcomes measuring skin clearance, itch, and quality of life were evaluated. Results: Both nonresponders (n = 548) and responders (n = 260) treated with abrocitinib had rapid and clinically meaningful improvement in skin clearance, itch, and quality of life compared with placebo. Conclusion: Patients with moderate-to-severe atopic dermatitis treated with abrocitinib who did not achieve an Investigator's Global Assessment 0/1 response at week 12 still experienced rapid, clinically meaningful improvements across several other validated measures of efficacy and quality of life.

Automated summary

In these trials, patients with moderate-to-severe atopic dermatitis treated with abrocitinib showed rapid and clinically meaningful improvements in skin clearance, itch, and quality of life, regardless of their response status.